Skip to main content
TipRanks
Go Ultimate75% OFF

ChronoScale (CHRN) AI Stock Analysis

786 Followers
CHRN

ChronoScale

(NASDAQ:CHRN)

Select Model
Rating:46Neutral
Price Target:$9.00â–¼(-7.60% Downside)
Action:reiterated
Date:11/06/26

The score is held down primarily by weak fundamentals (deep losses and higher leverage despite strong revenue growth) and clearly bearish technicals (below all major moving averages with negative MACD). Offsetting factors are the recent shift to positive operating/free cash flow and several positive corporate events strengthening the contracted AI infrastructure pipeline, but valuation cannot be supported with missing P/E and dividend yield data.

Positive Factors
Exceptional Revenue GrowthRevenue expansion of roughly 341% demonstrates strong recent demand and materially increases the potential scale of the business. Maintaining gross margin near 53% during this growth suggests the offering has reasonable unit economics, although continued execution is needed to convert scale into profits.
Negative Factors
Deepening Operating LossesThe company has not yet demonstrated operating leverage: rapid revenue growth is being outweighed by a cost structure that produces materially larger losses. Persistent negative profitability can consume capital, limit reinvestment capacity, and weaken the durability of the growth model.

ChronoScale Key Performance Indicators (KPIs)

Revenue by GeographyBreaks down sales across regions (U.S., Europe, Asia, etc.), showing where Ekso Bionics depends on demand, reimbursement rules, and local distribution partners. High concentration in a single region raises regulatory, reimbursement, or market risk; broader geographic mix signals more adoption, growth runway, and resilience to localized slowdowns.

$0.00$1.00M$2.00M$3.00M$4.00M$5.00MMar 21Jun 21Sep 21Dec 21Mar 22Jun 22Sep 22Dec 22Mar 23Jun 23Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26
Chart Insights

EKSO remains heavily dependent on Americas revenue, which drives large quarter-to-quarter swings and creates pronounced earnings volatility; EMEA emerged as a meaningful growth lane through 2024 but pulled back in 2025, undermining diversification gains. APAC is small and erratic—occasional upside but not a reliable contributor. Absent steadier international traction or clearer order/backlog visibility, continued reliance on lumpy Americas demand is the primary execution risk for near‑term revenue consistency.

Data provided by:The Fly

ChronoScale (CHRN) vs. SPDR S&P 500 ETF (SPY)

-100%0%100%200%300%400%500%600%700%CHRN+151.68%SPY+11.73%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$34.71M
Dividend Yield
―
Average Volume (3M)
148.08K
Price to Earnings (P/E)
―
Beta (1Y)
1.57
Revenue Growth
190.16%
EPS Growth
50.07%
Country
US
Employees
86
Sector
Technology
Sector Strength
61
Industry
Information Technology Services

ChronoScale Business Overview & Revenue Model

Company Description

ChronoScale Corporation designs and develops a compute platform to support artificial intelligence (AI) workloads. The company focuses on large-scale deployments and provides dedicated compute environments engineered for performance, consistency, and...

ChronoScale Earnings Call Summary

Earnings Call Date:Jul 28, 2025(Q2-2025)|% Change Since:115.01%|Next Earnings Date:Aug 03, 2026
Earnings Call SentimentNegative

The earnings call highlighted significant challenges, including a major decline in revenue and gross margin, alongside an increased net loss. Despite these challenges, there were positive developments in the personal health segment, strategic partnerships, and AI initiatives. However, the financial setbacks appear to overshadow the positive developments.

Positive Updates

Growth in Personal Health Segment
Personal Health product revenues grew by more than 50% year-over-year in the first half of 2025, driven by the Ekso Indego Personal device.

Negative Updates

Significant Revenue Decline
Second quarter 2025 revenue of $2.1 million was significantly lower compared to $5 million in the second quarter of 2024, due to delays in Enterprise Health sales.

Company Guidance

During the Ekso Bionics Second Quarter 2025 Financial Results Conference Call, the company reported a disappointing revenue of $2.1 million, a significant drop from $5 million in the same quarter of 2024, primarily due to short-term delays in completing multi-device Enterprise Health sales. Despite this decline, Ekso Indego Personal device sales partially offset the loss. Gross profit for Q2 2025 was $800,000, with a gross margin of approximately 40%, down from a gross profit of $2.6 million and a gross margin of 53% in Q2 2024. Operating expenses were reduced by 4% to $4.8 million. The net loss applicable to common stockholders increased to $2.7 million or $1.24 per share, from $2.4 million or $1.99 per share in the previous year. The company held $5.2 million in cash and restricted cash as of June 30, 2025. Ekso remains optimistic about closing deferred sales and expects Personal Health product revenues to grow significantly, having already increased by over 50% in the first half of 2025 compared to the previous year.

ChronoScale Financial Statement Overview

Summary

Revenue growth is extremely strong (~341% TTM) with gross margin holding near ~53% and cash flow has turned positive (OCF ~6.1M; FCF ~3.0M). However, profitability is still very weak (net margin about -136%) with losses expanding, leverage has stepped up (debt-to-equity ~0.75), and KPI insights point to a less resilient/recurring revenue mix and uneven regional execution.

Income Statement

22Negative

Balance Sheet

40Negative

Cash Flow

48Neutral
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue50.99M12.80M17.93M18.28M12.91M11.25M
Gross Profit1.15M6.84M9.51M9.08M6.21M6.75M
EBITDA-20.61M-9.81M-9.45M-13.20M-14.04M-9.09M
Net Income-55.46M-11.70M-11.33M-15.20M-15.08M-9.76M
Balance Sheet
Total Assets295.40M20.11M26.65M28.92M40.90M49.17M
Cash, Cash Equivalents and Short-Term Investments15.22M1.17M6.49M8.64M20.52M40.41M
Total Debt111.06M2.64M5.98M7.17M7.50M2.22M
Total Liabilities144.75M11.08M13.95M16.31M15.46M11.95M
Stockholders Equity150.65M9.03M12.71M12.61M25.44M37.22M
Cash Flow
Free Cash Flow3.05M-11.99M-9.88M-12.21M-14.88M-11.21M
Operating Cash Flow6.11M-11.80M-9.85M-12.05M-14.69M-11.16M
Investing Cash Flow-3.20M-188.00K-37.00K-157.00K-5.17M-59.00K
Financing Cash Flow1.43M6.63M7.77M348.00K038.71M

ChronoScale Technical Analysis

Technical Analysis SentimentNegative
Last Price9.74

Price Trends

50DMA16.62Negative
100DMA19.09Negative
200DMA16.18Negative

Market Momentum

MACD-1.98Positive
RSI32.15Neutral
STOCH10.93Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CHRN, the sentiment is Negative. The current price of 9.74 is below the 20-day moving average (MA) of 13.28, below the 50-day MA of 16.62, and below the 200-day MA of 16.18, indicating a bearish trend. The MACD of -1.98 indicates Positive momentum. The RSI at 32.15 is Neutral, neither overbought nor oversold. The STOCH value of 10.93 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CHRN.

ChronoScale Risk Analysis

ChronoScale disclosed 60 risk factors in its most recent earnings report. ChronoScale reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks
1.We are a "controlled company" under Nasdaq's corporate governance rules and, as a result, qualify for, and rely on, exemptions from certain corporate governance requirements. As a result, investors in the Company do not have the same protections afforded to stockholders of companies that are subject to such requirements.Q2, 2026
2.We are currently a "smaller reporting company" and the reduced reporting requirements applicable to such companies may make our common stock less attractive to investors.Q2, 2026
3.Provisions in our Articles (as defined below), our Bylaws (as defined below), and Nevada law may discourage a takeover attempt even if a takeover might be beneficial to our stockholders.Q2, 2026

ChronoScale Peers Comparison

Overall Rating

UnderperformOutperform
Sector (61)

Financial Indicators

CHRN against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *61Neutral$37.18B12.37-10.20%1.83%8.50%-7.62%
HBIOHBIO52Neutral$41.52M-3.53-130.06%―2.34%78.52%
CHRNCHRN46Neutral$1.42B―0.00%―190.16%50.07%
MLSSMLSS44Neutral$25.10M-6.67-122.29%―3.93%48.18%
LUCYLUCY42Neutral$6.73M-0.64-102.66%―56.89%52.61%

* Technology Sector Average

Performance Comparison

0%200%400%600%CHRNHBIOMLSSLUCYDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
CHRN and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
CHRNChronoscale Corporation9.745.71141.69%
HBIOHarvard Bioscience9.082.8846.52%
MLSSMilestone Scientific Inc0.28-0.04-13.44%
LUCYInnovative Eyewear, Inc.0.77-0.83-51.75%

ChronoScale Corporate Events

Executive/Board ChangesShareholder Meetings

ChronoScale Holdings Reports Results of Annual Stockholder Meeting

Neutral
Nov 6, 2026

On November 6, 2026, ChronoScale Holdings Corporation held its annual meeting of stockholders. Stockholders elected Wes Cummins, Ella Benson, Ying Cenly Chen, William M. Clancy, Douglas Miller, Richard Nottenburg and Andrew Schaap as directors to ser...

Business Operations and StrategyExecutive/Board ChangesM&A Transactions

ChronoScale Director Resigns Following Ekso Bionics Divestiture

Neutral
Oct 6, 2026

ChronoScale Holdings Corporation reported that in connection with the sale of its wholly owned subsidiary Ekso Bionics, Inc. completed on September 30, 2026, Scott Davis resigned from the company’s board of directors effective October 3, 2026, while...

Business Operations and StrategyExecutive/Board ChangesM&A TransactionsRegulatory Filings and Compliance

ChronoScale expands AI infrastructure contracts, refines growth focus

Positive
Oct 2, 2026

ChronoScale completed the sale of its Ekso Bionics business unit on September 30, 2026, and subsequently terminated Ekso’s Chief Operating Officer, Jason C. Jones, on the same date, with Ekso entering into a severance and release agreement granting h...

Business Operations and StrategyPrivate Placements and Financing

ChronoScale amends term loan, extends debt maturity

Positive
Sep 16, 2026

On September 12, 2026, ChronoScale Intermediate, LLC and Ekso Bionics, Inc. amended their existing $2.0 million secured term loan agreement with B. Riley Commercial Capital, LLC, under which the full principal amount remained outstanding at the time...

Business Operations and StrategyRegulatory Filings and Compliance

ChronoScale, Microsoft expand AI infrastructure partnership deployment

Positive
Aug 27, 2026

On August 27, 2026, ChronoScale announced a strategic partnership with Microsoft to develop a 50-megawatt AI compute deployment in North America, integrating NVIDIA GB300 NVL72 systems and advanced liquid-cooling infrastructure. The project is design...

Business Operations and StrategyExecutive/Board Changes

ChronoScale confirms CFO role with new compensation package

Positive
Aug 18, 2026

On August 16, 2026, ChronoScale Corporation entered into an Offer of Continued Employment and a Covenants Agreement with Chief Financial Officer Jerome Wong, confirming his role and setting his annual base salary at $400,000 with a target performance...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 06, 2026